Asset Details
Do you wish to reserve the book?
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Do you wish to request the book?
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012
Overview
In this randomized trial involving adults with Crohn's disease in whom anti–tumor necrosis factor therapy had failed, ustekinumab, an antibody against interleukin-12 and 23, was associated with increased response rates, as compared with placebo.
Crohn's disease is a chronic inflammatory bowel disease.
1
One third of patients do not have a response to initial treatment with tumor necrosis factor (TNF) antagonists (primary nonresponse)
2
–
6
; another one third have a transient response
2
,
4
,
6
and require dose escalation or a switch to another therapy (secondary nonresponse).
7
,
8
Patients with primary nonresponse are unlikely to benefit from another TNF antagonist. Patients with secondary nonresponse who switch to a second TNF antagonist are less likely to have a response than are patients who have not received a TNF antagonist.
4
,
6
These represent difficult clinical problems.
Preclinical studies . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Biological and medical sciences
/ Crohn Disease - classification
/ Crohn Disease - drug therapy
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Male
/ Patients
/ Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
